SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences in May 2024. Details of the presentations can be found below.
H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
Location: The Nasdaq Headquarters, New York City
Presenter: Mark Erlander, CEO
Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Presenter: Mark Erlander, CEO
Interested parties can register for and access the live webcasts for these conferences by visiting the “Events” section of the Cardiff Oncology website. The webcast replays will be available after the conclusion of the respective presentations.
Cardiff Oncology Contact:
jlevine@cardiffoncology.com
grace@taftcommunications.com